| Risperdal Consta (risperidone depot formulation) / J&J |
NCT00458367: RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice |
|
|
| Completed | N/A | 5296 | Europe | Open label risperidone long acting injectable | Janssen Pharmaceutica N.V., Belgium | Schizophrenia, Psychotic Disorders, Schizoaffective Disorder | | 10/06 | | |
NCT00246194: Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA) |
|
|
| Completed | N/A | 532 | US | risperidone (RISPERDAL CONSTA), RISPERDAL CONSTA | Janssen, LP | Schizophrenia | 11/07 | 11/07 | | |
e-STAR, NCT00774085: An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone |
|
|
| Completed | N/A | 408 | Europe | No intervention was given | Janssen Cilag N.V./S.A. | Schizophrenia | 12/07 | 12/07 | | |
NCT00294008: A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR) |
|
|
| Completed | N/A | 230 | RoW | Risperdal Consta | Janssen Korea, Ltd., Korea | Schizophrenia, Tranquilizing Agents, Mental Disorders, Therapeutic Uses, Physiological Effects of Drugs, Psychotropic Drugs, Antipsychotic Agents | 06/09 | 06/09 | | |
NCT01894984: An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia |
|
|
| Terminated | N/A | 640 | RoW | Risperidone, Risperdal Consta, Oral atypical anti-psychotic | Xian-Janssen Pharmaceutical Ltd. | Schizophrenia | 12/09 | 12/09 | | |
NCT00845572: The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center |
|
|
| Completed | N/A | 30 | US | Consta Club, Risperdal Consta | The University of Texas Health Science Center at San Antonio, Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia, Schizoaffective | 06/10 | 06/10 | | |
NCT01698216: Switching From Consta® to Sustenna® in Patients With Schizophrenia |
|
|
| Completed | N/A | 50 | RoW | | Seoul National University Hospital | Schizophrenia | 05/15 | 05/15 | | |
